Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$18.01 - $23.78 $59,613 - $78,711
3,310 Added 30.8%
14,058 $303,000
Q3 2022

Nov 14, 2022

SELL
$16.32 - $26.37 $14,100 - $22,783
-864 Reduced 7.44%
10,748 $208,000
Q2 2022

Aug 11, 2022

SELL
$18.54 - $37.29 $153,659 - $309,059
-8,288 Reduced 41.65%
11,612 $231,000
Q1 2022

May 16, 2022

SELL
$23.94 - $33.74 $57,623 - $81,212
-2,407 Reduced 10.79%
19,900 $594,000
Q4 2021

Feb 09, 2022

SELL
$21.19 - $31.29 $27,292 - $40,301
-1,288 Reduced 5.46%
22,307 $520,000
Q3 2021

Nov 15, 2021

SELL
$27.36 - $35.98 $45,964 - $60,446
-1,680 Reduced 6.65%
23,595 $736,000
Q2 2021

Aug 11, 2021

SELL
$28.9 - $36.87 $268,943 - $343,112
-9,306 Reduced 26.91%
25,275 $889,000
Q1 2021

May 07, 2021

BUY
$32.03 - $42.85 $8,199 - $10,969
256 Added 0.75%
34,581 $1.22 Million
Q4 2020

Feb 03, 2021

BUY
$31.56 - $42.16 $319,071 - $426,237
10,110 Added 41.75%
34,325 $1.29 Million
Q3 2020

Nov 04, 2020

BUY
$23.19 - $41.61 $87,727 - $157,410
3,783 Added 18.52%
24,215 $808,000
Q2 2020

Aug 05, 2020

SELL
$14.82 - $29.92 $90,327 - $182,362
-6,095 Reduced 22.98%
20,432 $541,000
Q1 2020

May 06, 2020

BUY
$11.67 - $27.23 $8,997 - $20,994
771 Added 2.99%
26,527 $434,000
Q4 2019

Feb 07, 2020

BUY
$16.92 - $28.96 $7,072 - $12,105
418 Added 1.65%
25,756 $655,000
Q3 2019

Nov 04, 2019

BUY
$20.0 - $31.88 $2,960 - $4,718
148 Added 0.59%
25,338 $507,000
Q2 2019

Aug 07, 2019

SELL
$30.67 - $37.86 $114,153 - $140,914
-3,722 Reduced 12.87%
25,190 $812,000
Q1 2019

May 01, 2019

BUY
$22.22 - $32.21 $27,841 - $40,359
1,253 Added 4.53%
28,912 $931,000
Q4 2018

Feb 04, 2019

BUY
$20.9 - $32.57 $135,390 - $210,988
6,478 Added 30.58%
27,659 $678,000
Q3 2018

Oct 25, 2018

BUY
$29.29 - $36.87 $114,933 - $144,677
3,924 Added 22.74%
21,181 $698,000
Q2 2018

Aug 02, 2018

BUY
$28.9 - $37.31 $498,727 - $643,858
17,257 New
17,257 $613,000

Others Institutions Holding ALBO

About ALBIREO PHARMA, INC.


  • Ticker ALBO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 19,612,500
  • Description
  • Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as we...
More about ALBO
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.